Routine annual meeting results with no surprises. The 2M share increase to the equity plan is small relative to market cap and standard for ongoing compensation. No trading catalyst here, monitor next quarterly earnings for fundamental performance.
EXEL drugs
EXEL drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 1 $50.20entry
- T+1 · 6mo ago −3.41%α −3.55% · $48.49
- T+5 · 5mo ago +4.98%α +7.73% · $52.70
- T+20 · 5mo ago +8.13%α +10.44% · $54.28
- T+60 · 3mo ago +12.59%α +11.62% · $56.52
Price Chart
How similar events traded
Executive Summary
Exelixis held its 2026 Annual Meeting on May 26, 2026, where stockholders approved the amendment and restatement of the 2017 Equity Incentive Plan, adding 2,000,000 new shares to the share reserve, and ratified the selection of Ernst & Young as independent auditor. All 11 director nominees were elected, and the advisory Say on Pay proposal passed. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved the amendment and restatement of the 2017 Equity Incentive Plan, adding 2,000,000 new shares to the share reserve (total share reserve now 75,953,064 shares).
- All 11 director nominees were elected with strong support (lowest 'for' vote was 180,367,648 for Maria C. Freire).
- Ratification of Ernst & Young as independent auditor passed with 222,343,120 votes for.
- Advisory Say on Pay proposal passed with 163,104,135 votes for (43,156,553 against).
- No departures, appointments, or changes to executive compensation were reported.
Financial Impact
2,000,000 new shares authorized for equity grants, representing approximately 0.6% of shares outstanding based on a $12.9B market cap, minimal dilution.
Risk Factors
- Say on Pay received 20.9% against votes (43.2M), which is notable but non-binding and below typical threshold for concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000939767-26-000074 |
| Exhibit: exel-20260526.htm | 0000939767-26-000074 |
| Document: 0000939767-26-000074-index-headers.html | 0000939767-26-000074 |
| Document: 0000939767-26-000074-index.html | 0000939767-26-000074 |
| Document: 0000939767-26-000074.txt | 0000939767-26-000074 |
Track record
16 reports on EXEL
0 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +21.97% at T+60 after the Feb 28, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $70.58 to $70.70 Now $67.10 −4.93% ▲ +0.17% −1.15% vs SPY
- Nov 9, 20267d ago SC 13D/A Bearish 5/10 Entry $70.58 to $70.70 Now $67.10 +4.93% ▼ −0.17% +1.15% vs SPY
- Oct 29, 202618d ago 8-K Neutral 5/10 Entry $69.39 to $70.13 Now $67.10 −3.30% ▲ +1.07% +1.55% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 2/10 Entry $64.58 to $65.31 Now $67.10 +3.90% ▲ +1.13% +2.31% vs SPY
- Oct 12, 20265w ago Institutional Cluster Neutral 3/10 Entry $59.82 to $59.51 Now $67.10 +12.17% ▼ −0.52% −0.51% vs SPY
- Sep 11, 20269w ago 8-K Bearish 6/10 Entry $56.12 to $56.21 Now $67.10 −19.57% ▼ −0.16% −0.61% vs SPY
- Jun 3, 202623w ago Insider Cluster Neutral 2/10 Entry $52.39 to $52.69 Now $67.10 +28.08% ▲ +0.57% +3.17% vs SPY
- May 29, 202624w ago 8-K Neutral 3/10 Viewing Entry $50.20 to $48.49 Now $67.10 +33.67% ▼ −3.41% −3.55% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
- May 28, 202624w ago Insider Cluster Neutral 3/10 Entry $50.32 to $50.28 Now $67.10 +33.35% ▼ −0.08% −0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers